Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Brain transcriptomic and proteomic analyses in an <em>in vivo</em> AD model further elucidate the role of the sigma-2 receptor modulator CT1812 in Alzheimer’s disease

Sunday, July 16, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study presented at the 2023 Alzheimer’s Association International Conference highlights the role of the sigma-2 receptor modulator CT1812 in Alzheimer's disease. Through brain transcriptomic and proteomic analyses in an in vivo model, researchers aim to deepen the understanding of CT1812's effects. This research could pave the way for new therapeutic strategies in treating Alzheimer's.
Price reaction · baseline $1.73 (2023-07-14 close) · clean, no other CGTX news in the window
day 0 close · peak
+4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • CT1812 shows promise in Alzheimer's disease treatment.
  • Research presented at a prestigious international conference.
  • In-depth analyses provide valuable insights into AD mechanisms.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Di Caro V, Cho E, Caldwell J, et al. Brain transcriptomic and proteomic analyses in an in vivo AD model further elucidate the role of the sigma-2 receptor modulator CT1812 in Alzheimer’s disease . Poster presented at: 2023 Alzheimer’s Association’s International Conference (AAIC) ; Amsterdam, The Netherlands.

Frequently Asked Questions

What is CT1812?

CT1812 is a sigma-2 receptor modulator being studied for its effects on Alzheimer's disease.

Where was the research on CT1812 presented?

The research was presented at the 2023 Alzheimer’s Association International Conference in Amsterdam.

What type of analyses were conducted in the study?

The study involved brain transcriptomic and proteomic analyses in an in vivo Alzheimer's model.

What is the significance of this research?

The research aims to provide insights into the mechanisms of Alzheimer's and potential treatments.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare CT1812 Alzheimer's disease sigma-2 receptor 2023 AAIC brain analysis
Last updated: Jul 16, 2023

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →